Hussman Strategic Advisors’s Praxis Precision Medicines PRAX Stock Holding History

Hussman Strategic Advisors’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.41M	Hold	4,200	–	–	0.32%	148
2026 Q1	$1.35M	Sell	4,200 -4,200	-50%	-$1.3M	0.29%	155
2025 Q4	$2.48M	Sell	8,400 -2,100	-20%	-$391K	0.6%	56
2025 Q3	$557K	Hold	10,500	–	–	0.12%	238
2025 Q2	$442K	Hold	10,500	–	–	0.1%	180
2025 Q1	$398K	Hold	10,500	–	–	0.1%	201
2024 Q4	$808K	Sell	10,500 -10,500	-50%	-$760K	0.24%	151
2024 Q3	$1.21M	Hold	21,000	–	–	0.3%	145
2024 Q2	$869K	Buy	+21,000	New	+$992K	0.24%	154

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Hussman Strategic Advisors's PRAX Position: Q2 2026 in Review

Hussman Strategic Advisors held its Praxis Precision Medicines (PRAX) position steady in Q2 2026 at 4,200 shares worth $1.41M. The position accounts for 0.32% of the portfolio, ranked #148.

Hussman Strategic Advisors first reported a position in PRAX in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.48M in Q4 2025. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

Hussman Strategic Advisors held 4,200 shares of Praxis Precision Medicines worth $1.41M as of Q2 2026.
Hussman Strategic Advisors left its Praxis Precision Medicines share count unchanged in Q2 2026.
Praxis Precision Medicines made up 0.32% of Hussman Strategic Advisors's portfolio in Q2 2026, its #148 holding.
Hussman Strategic Advisors first reported a position in Praxis Precision Medicines in Q2 2024 and has held it in 9 quarters since.
Hussman Strategic Advisors's Praxis Precision Medicines position peaked at $2.48M in Q4 2025.
309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.